Chee Keong SeeDr. Malaysia

Chee Keong SeeDr.
Dr See Chee Keong, graduated from University Putra Malaysia in 2006, completed MRCP (UK) in 2012 and Diabetes & Endocrinology fellowship in 2019. He is currently Consultant Physician and Endocrinologist with practice in Subang Jaya Medical Centre and Park City Medical Centre and Hospital Sultan Haji Ahmad Shah, Temerloh. He is currently the Honorary Treasurer of Malaysian Endocrine and Metabolic Society (2024-2026). He is an active peer reviewer with the Journal of ASEAN Federation of Endocrine Society (JAFES) and steering committee member of the Changing Diabetes in Children program. He has avid interest in conducting clinical audits and research and participates actively educational programmes nationally and regionally. He has special interest in Men’s Health Issues, Young Diabetes, Diabetes Technology, Thyroid disorders and Acromegaly.

21 MARCH

Time Session
10:20
11:10
Oral Presentation 4: Metabolic Synergy: Diabetes & Obesity Management
Chee Keong SeeMalaysia Moderator AI and Digital Diabetes Care: Awareness, Utilisation and Perspectives from MalaysiaMalaysia’s substantial burden of Type 2 Diabetes (T2D) necessitates a transition from a conventional “standard-of-care” approach toward a more individualized “precision-of-care” model. In this context, Artificial Intelligence (AI)–driven Clinical Decision Support Systems (CDSS) are emerging as promising tools to address persistent clinical and treatment inertia. AI in Insulin Titration Recent evidence evaluating a real-time AI-assisted insulin titration system for glycaemic control in patients with T2D demonstrates considerable clinical potential. By integrating Continuous Glucose Monitoring (CGM) data with historical insulin dosing patterns, the system generates individualized titration recommendations. Clinical findings indicate non-inferiority to senior endocrinologists in insulin dose adjustment. Notably, use of the system was associated with improvements in Time in Range (TIR), enhanced day-to-day glycaemic stability, and a significant reduction in nocturnal hypoglycaemia. Specialist Perspective Malaysian endocrinologists have expressed cautious optimism regarding the integration of AI into diabetes management. Rather than functioning as a replacement for clinician expertise or doctor–patient interaction, AI-based systems are regarded as adjunctive decision-support tools. These systems may alleviate cognitive and administrative burden, thereby allowing clinicians to allocate greater attention to complex case management, comorbidity optimization, and individualized patient counselling. Adoption Drivers and Barriers The successful implementation of AI-driven CDSS is influenced by both technical and socio-behavioral factors. Adoption is strongly associated with performance expectancy, particularly perceived improvements in efficiency and clinical productivity, as well as positive peer influence within the medical community. Conversely, concerns surrounding data privacy, workflow disruption, system interoperability, and digital literacy—especially among older patient populations—remain significant barriers to widespread integration. Future Directions To translate technological innovation into sustainable clinical impact, strategic priorities should include seamless integration with existing Electronic Medical Record (EMR) systems, robust data governance and cybersecurity frameworks, and structured AI competency training for healthcare professionals. Ultimately, AI should be conceptualized not as a substitute for clinical judgment, but as a complementary enabler of scalable, precise, and patient-centered diabetes care in Malaysia.
Dicky L. TahaparyIndonesia Moderator Precision Diabetes Clustering for Young-Onset Diabetes (in Indonesia Populations)
201BC

22 MARCH

Time Session
14:00
15:30
ESROC–MEMS Joint Symposium
Digital Endocrinology, Wearables, and Future Therapeutics in Asia
Waye Hann KangMalaysia Moderator
Yi-Sun YangTaiwan Moderator Impaired Fasting Glucose and Musculoskeletal DisordersThe Continuum of Glycemic Dysregulation and Musculoskeletal Health: From Impaired Fasting Glucose to Established Diabetes. As the global medical community transitions into the "Next ERA" of endocrinology, there is an urgent need to broaden our focus beyond traditional microvascular and macrovascular complications toward the pervasive, yet often neglected, musculoskeletal (MS) burden associated with dysglycemia. While the debilitating effects of established Type 2 Diabetes Mellitus (T2DM) on physical function are well-documented, emerging clinical evidence suggests that the musculoskeletal system is an early "silent" target of metabolic injury, with pathological changes manifesting as early as the Impaired Fasting Glucose (IFG) stage. This presentation explores the MS burden across the full glycemic spectrum, highlighting how the transition from normoglycemia to IFG, and ultimately to T2DM, correlates with a progressive increase in chronic pain, structural tissue damage, and functional disability.
  • Continuous Glucose Monitoring (CGM) in Asia: Behavior Change, Physician Workflow, and New Care Models
    Jun-Sing WangTaiwan Speaker Continuous Glucose Monitoring (CGM) in Asia: Behavior Change, Physician Workflow, and New Care Models
  • AI and Digital Diabetes Care: Awareness, Utilisation and Perspectives from Malaysia
    Chee Keong SeeMalaysia Speaker AI and Digital Diabetes Care: Awareness, Utilisation and Perspectives from MalaysiaMalaysia’s substantial burden of Type 2 Diabetes (T2D) necessitates a transition from a conventional “standard-of-care” approach toward a more individualized “precision-of-care” model. In this context, Artificial Intelligence (AI)–driven Clinical Decision Support Systems (CDSS) are emerging as promising tools to address persistent clinical and treatment inertia. AI in Insulin Titration Recent evidence evaluating a real-time AI-assisted insulin titration system for glycaemic control in patients with T2D demonstrates considerable clinical potential. By integrating Continuous Glucose Monitoring (CGM) data with historical insulin dosing patterns, the system generates individualized titration recommendations. Clinical findings indicate non-inferiority to senior endocrinologists in insulin dose adjustment. Notably, use of the system was associated with improvements in Time in Range (TIR), enhanced day-to-day glycaemic stability, and a significant reduction in nocturnal hypoglycaemia. Specialist Perspective Malaysian endocrinologists have expressed cautious optimism regarding the integration of AI into diabetes management. Rather than functioning as a replacement for clinician expertise or doctor–patient interaction, AI-based systems are regarded as adjunctive decision-support tools. These systems may alleviate cognitive and administrative burden, thereby allowing clinicians to allocate greater attention to complex case management, comorbidity optimization, and individualized patient counselling. Adoption Drivers and Barriers The successful implementation of AI-driven CDSS is influenced by both technical and socio-behavioral factors. Adoption is strongly associated with performance expectancy, particularly perceived improvements in efficiency and clinical productivity, as well as positive peer influence within the medical community. Conversely, concerns surrounding data privacy, workflow disruption, system interoperability, and digital literacy—especially among older patient populations—remain significant barriers to widespread integration. Future Directions To translate technological innovation into sustainable clinical impact, strategic priorities should include seamless integration with existing Electronic Medical Record (EMR) systems, robust data governance and cybersecurity frameworks, and structured AI competency training for healthcare professionals. Ultimately, AI should be conceptualized not as a substitute for clinical judgment, but as a complementary enabler of scalable, precise, and patient-centered diabetes care in Malaysia.
  • Next-Generation Biomarkers for Thyroid Cancer and Endocrine Tumors
    Yen-Bo LinTaiwan Speaker Next-Generation Biomarkers for Thyroid Cancer and Endocrine Tumors
  • Future Endocrine Therapeutics in Southeast Asia: From Super Mono, Dual to Triple Incretin Agonists and Beyond
    Siew Hui FooMalaysia Speaker Future Endocrine Therapeutics in Southeast Asia: From Super Mono, Dual to Triple Incretin Agonists and BeyondThe role of incretin-based therapy is taking the front seat globally due to the high prevalence of obesity, diabetes and related complications worldwide. Similar scene is expected to take place in South East Asia that is facing the escalating burden of obesity driving up the already high burden of type 2 diabetes especially in the younger population despite consisting of relatively small countries in areas and population. This poses adverse socio-economic impact to the region due to increased risk of premature complications and death among the young in a region that is largely still developing. The arrival of incretin-based therapy into South East Asia since the first daily glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection in 2010 has picked up its pace in the last 5 years with the entry of weekly GLP-1 RA injection, oral GLP-1 RA and GLP-1 RA / GIP (glucose-dependent insulinotropic polypeptide) injection. This lecture will address the evidence behind its efficacy, tolerability as well as cardiovascular effects of these agents in the Asian populations. The future shift to the more potent high-dose GLP-1 receptor mono-agonist, dual, triple incretin receptor multi-agonist and beyond as these agents are approved for treatment for the twin epidemics of type 2 diabetes, obesity and related complications will be discussed along with the challenges especially on unequitable access, healthcare disparities, unregulated dispensing and the importance of a strengthened health system with multi-sectoral cooperation at the regional level to mitigate these issues.
  • Discussion
103